In the phase III SIRROUND-T study, treatment with the IL-6-specific antibody sirukumab was well tolerated and showed clinical efficacy in patients with RA refractory to anti-TNF therapy. At week 16, 40% (117 of 292) of patients treated with 50 mg sirukumab every 4 weeks and 45% (132 of 292) of patients treated with 100 mg sirukumab every 2 weeks achieved the primary outcome of ≥20% improvement according to ACR criteria (ACR20 response), compared with 24% (71 of 294) of patients treated with placebo. Adverse event incidences were similar across groups, with the most common being injection-site erythema.
References
Aletaha, D. et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet http://dx.doi.org/10.1016/S0140-6736(17)30401-4 (2017)
Rights and permissions
About this article
Cite this article
McHugh, J. Sirukumab effective in patients refractory to anti-TNF therapy. Nat Rev Rheumatol 13, 197 (2017). https://doi.org/10.1038/nrrheum.2017.31
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.31
